This meta-analysis of RCTs examines cardiovascular and renal outcomes in patients with and without CKD and includes results from the most recently published clinical trials with SGLT-2 inhibitors in patients with and without diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.